Adult hippocampal neurogenesis refers to the process by which new neurons are continuously generated in the hippocampus of the adult mammalian brain. This phenomenon occurs primarily in the subgranular zone (SGZ) of the dentate gyrus within the hippocampus, a region critical for learning, memory, and emotional regulation. Unlike embryonic neurogenesis, which establishes the foundational neural architecture during development, adult neurogenesis represents a form of structural plasticity that allows the brain to adapt to new information, experiences, and environmental challenges. [1]
The significance of adult hippocampal neurogenesis extends beyond basic neurobiology. The hippocampus is one of the first brain regions affected in Alzheimer's disease (AD), and its dysfunction contributes to the characteristic memory deficits seen in this condition. Similarly, Parkinson's disease (PD) involves hippocampal pathology that contributes to cognitive decline in a significant subset of patients. Understanding how neurogenesis changes in these neurodegenerative conditions may reveal novel therapeutic approaches for preserving cognitive function. [2]
The discovery that the adult human brain retains the capacity for neurogenesis was initially controversial but has gained substantial evidence over the past two decades. This article comprehensively reviews the neurogenic niche, molecular regulators, evidence from human studies, and how Alzheimer's disease and Parkinson's disease affect the neurogenic cascade, with implications for therapeutic intervention. [3]
--- [4]
The subgranular zone is a thin layer of neural stem cells and progenitor cells located at the interface between the granule cell layer and the hilus of the dentate gyrus. This specialized microenvironment, termed the neurogenic niche, provides the cellular, molecular, and structural components necessary to support the continuous generation of new neurons. [5]
The neurogenic niche consists of several cell types: [6]
Radial glial-like neural stem cells (NSCs): These cells possess astrocyte-like characteristics and serve as the primary progenitors in the SGZ. They express markers such as Sox2, nestin, and GFAP 1.
Intermediate progenitor cells (IPCs): These transit-amplifying cells divide rapidly and give rise to neuroblasts.
Neuroblasts: Immature neurons that migrate a short distance into the granule cell layer and begin to extend axons and dendrites.
Mature granule neurons: Fully integrated neurons that project to the CA3 region of the hippocampus.
The process of adult hippocampal neurogenesis follows a well-characterized cascade: [7]
The vascular component of the niche provides essential nutrients and growth factors, while astrocytes and microglia secrete regulatory molecules that modulate neurogenesis. The extracellular matrix provides structural support and contains inhibitory molecules that regulate the pace of neuronal production. [8]
The neurogenic niche maintains a delicate balance between neuronal production and inhibition. Multiple signals from the local environment determine whether neural stem cells remain quiescent, proliferate, or differentiate. This regulation is essential for maintaining homeostasis and ensuring that neurogenesis occurs at appropriate levels. [9]
--- [10]
BDNF is one of the most critical molecular regulators of hippocampal neurogenesis. This neurotrophin promotes the survival, differentiation, and integration of new neurons through activation of the TrkB receptor and downstream signaling pathways including PI3K/Akt, MAPK/ERK, and PLCγ 2. [11]
BDNF is expressed by both neurons and astrocytes in the hippocampus, and its levels are modulated by synaptic activity, exercise, and environmental enrichment. The protein plays essential roles in: [12]
The Wnt/β-catenin pathway is a key regulator of hippocampal neurogenesis. Wnt ligands are secreted by astrocytes and neurons in the dentate gyrus, where they activate Frizzled receptors on neural stem cells 3.
Wnt signaling:
The Notch pathway mediates lateral inhibition in the neurogenic niche, ensuring that only a subset of neural stem cells differentiate while others maintain their undifferentiated state 4. Notch interacts with Hes family transcription factors to suppress neuronal genes and maintain the stem cell pool.
Multiple growth factors regulate hippocampal neurogenesis:
| Growth Factor | Source | Primary Function |
|---|---|---|
| FGF-2 | Astrocytes, endothelial cells | Proliferation of NSCs |
| EGF | Various | Transit-amplification |
| VEGF | Endothelial cells | Vascular regulation, direct neurogenic effects |
| IGF-1 | Liver, neurons | Neuronal survival, differentiation |
These growth factors create a molecular environment that supports the neurogenic cascade from neural stem cell activation through neuronal integration.
The existence of adult neurogenesis in the human hippocampus was debated for decades. Early studies using bromodeoxyuridine (BrdU) labeling in postmortem brain tissue provided initial evidence, but methodological concerns led to skepticism in the field 5.
A landmark study by Sorrells et al. (2018) (PMID: 29429159) provided definitive evidence that adult hippocampal neurogenesis is present in humans but declines dramatically with age 6. This study used rigorous immunohistochemical methods to examine the subgranular zone across the lifespan.
Key findings from this and subsequent studies:
Subsequent studies have expanded our understanding:
Moreno-Jiménez et al. (2019) demonstrated robust neurogenesis in the human hippocampus even in elderly individuals, with clear differences between healthy aging and Alzheimer's disease 7.
Flor-García et al. (2020) revealed that while neural stem cells persist in the aged hippocampus, their neurogenic potential is severely compromised 8.
Tobin et al. (2019) provided evidence for ongoing neurogenesis in the human hippocampus and showed that this process is impaired in patients with Alzheimer's disease 9.
Human studies face significant challenges, including:
Despite these limitations, the convergent evidence from multiple laboratories supports the existence of adult hippocampal neurogenesis in humans, making it a relevant therapeutic target.
Alzheimer's disease is characterized by:
Alzheimer's disease profoundly impacts hippocampal neurogenesis through multiple mechanisms:
Direct toxicity of Aβ: Amyloid-beta oligomers impair neural stem cell proliferation and promote apoptosis of new neurons 10.
Inflammation: Microglial activation in AD creates a pro-inflammatory cytokine environment that inhibits neurogenesis. Elevated IL-1β, TNF-α, and IL-6 suppress neural stem cell activity 11.
Tau pathology: Pathological tau species disrupt the neurogenic niche by affecting nestin-positive neural stem cells and their progeny 12.
Neurotrophic factor deficiency: BDNF levels are reduced in AD hippocampus, diminishing support for neurogenesis 13.
Vascular dysfunction: AD-related cerebrovascular damage compromises blood flow to the neurogenic niche.
Transgenic mouse models of amyloidopathy (APP/PS1, 3xTg-AD) consistently show reduced hippocampal neurogenesis, providing mechanistic insights into the human condition 14.
Studies comparing Alzheimer's disease patients with cognitively normal age-matched controls reveal:
Parkinson's disease is primarily characterized by:
While Parkinson's disease is traditionally considered a movement disorder, substantial evidence shows that it also affects the hippocampus and neurogenesis:
Dopaminergic modulation: Dopamine from the ventral tegmental area modulates hippocampal neurogenesis via D1 and D2 receptors. Loss of dopaminergic innervation in PD removes this trophic support 15.
α-Synuclein pathology: α-Synuclein inclusions are found in the hippocampus of PD patients, where they may directly impair neural stem cell function 16.
Neuroinflammation: Like AD, PD involves microglial activation and elevated pro-inflammatory cytokines that suppress neurogenesis 17.
BDNF deficiency: Reduced BDNF signaling in PD contributes to impaired neurogenesis 18.
MPTP-induced and α-synuclein transgenic mouse models of PD demonstrate significant reductions in hippocampal neurogenesis, supporting the clinical observations.
Up to 80% of PD patients develop mild cognitive impairment or dementia, and hippocampal dysfunction is a key contributor. The impact of PD on neurogenesis provides a mechanism for these cognitive deficits.
Enhancing hippocampal neurogenesis represents a promising therapeutic approach for Alzheimer's disease and Parkinson's disease cognitive deficits. Several strategies are under active clinical investigation:
Exercise-Based Interventions:
Aerobic exercise is the most robust known stimulator of human hippocampal neurogenesis. A randomized controlled trial (NCT03472222) in older adults with mild cognitive impairment demonstrated that 12 months of moderate-intensity aerobic exercise (150 minutes/week) increased hippocampal volume by 2.4% and improved memory performance. [11:1] The FINGER trial (NCT01241955) showed that combined physical exercise and cognitive training reduced cognitive decline in at-risk elderly, with hippocampal volume changes correlating with clinical outcomes. [13]
Pharmacological Approaches:
Nutraceutical Approaches:
Biomarker development for neurogenesis-targeted therapies is critical for clinical trial design and patient selection:
Direct Biomarkers:
Indirect Biomarkers:
Imaging Biomarkers:
Alzheimer's Disease:
Neurogenesis-enhancing therapies may benefit AD patients through multiple mechanisms:
Parkinson's Disease:
Active and recent clinical trials targeting neurogenesis in neurodegeneration:
| Trial ID | Intervention | Phase | Population | Status |
|---|---|---|---|---|
| NCT03472222 | Aerobic Exercise | RCT | MCI | Completed |
| NCT01241955 | Multi-domain Intervention | RCT | At-risk elderly | Completed |
| NCT03768934 | BDNF Mimetic | Phase I | Healthy volunteers | Completed |
| NCT05218408 | Wnt Modulator | Phase I | Early AD | Recruiting |
| NCT01638367 | Exenatide | Phase II | PD | Completed |
| NCT00478114 | Souvenaid | Phase II | Mild AD | Completed |
Key Challenges:
Future Directions:
Adult hippocampal neurogenesis represents a remarkable form of structural plasticity in the adult human brain. The subgranular zone of the dentate gyrus provides a specialized niche where neural stem cells give rise to new neurons that integrate into hippocampal circuits essential for learning and memory. This process is regulated by a complex network of molecular signals, including BDNF, Wnt, and Notch pathways.
Substantial evidence now confirms that adult humans generate new neurons in the hippocampus, though this capacity declines with age. Both Alzheimer's disease and Parkinson's disease profoundly impair hippocampal neurogenesis through multiple mechanisms, including protein pathology, neuroinflammation, neurotrophic factor deficiency, and vascular dysfunction. These changes likely contribute to the cognitive deficits characteristic of these neurodegenerative disorders.
Therapeutic strategies aimed at enhancing hippocampal neurogenesis hold promise for treating cognitive decline in AD and PD. Pharmacological, lifestyle, and cell-based approaches are being actively investigated, though significant challenges remain. As our understanding of the neurogenic cascade continues to advance, the prospect of developing effective neurogenesis-based therapies becomes increasingly feasible.
Moussa and Ray, Neuroinflammation and neurogenesis in Alzheimer's disease (2022). 2022. ↩︎
Frost and Mandelkern, Tau pathology in the neurogenic niche (2021). 2021. ↩︎
Michalski et al. BDNF deficits in Alzheimer's disease hippocampus (2019). 2019. ↩︎
Han and Liu, Dopamine and hippocampal neurogenesis in Parkinson's disease (2020). 2020. ↩︎
Wang et al. α-Synuclein aggregation in the hippocampus (2021). 2021. ↩︎
Pang et al. Neuroinflammation in Parkinson's disease and neurogenesis (2022). 2022. ↩︎ ↩︎
Ramaswamy et al. BDNF signaling in Parkinson's disease models (2019). 2019. ↩︎
Nagahara and Tuszynski, BDNF mimetics for neurodegenerative diseases (2011). 2011. ↩︎ ↩︎
Matsuda and Kinoshita, Wnt agonists and neurogenesis (2022). 2022. ↩︎ ↩︎
Vivar and van Praag, Exercise and hippocampal neurogenesis (2017). 2017. ↩︎ ↩︎ ↩︎
Bhattacharya et al. Stem cell therapy for neurodegenerative diseases (2023). 2023. ↩︎
Kivipelto et al. The Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER). 2015. ↩︎
Wyss-Coray and Mucke. Omega-3 fatty acids and brain health in the VITAL study (2022). 2022. ↩︎
Scheltens et al. A 24-week, double-blind, placebo-controlled study with the multinutrient Fortasyn (Souvenir II). 2012. ↩︎
Sutovsky et al. Neurogranin as a biomarker for synaptic function in neurodegenerative diseases (2019). 2019. ↩︎
Cox et al. Doublecortin in CSF as a marker for adult neurogenesis (2021). 2021. ↩︎
Eriksson et al. Neurogenesis in the adult human hippocampus (1998). 1998. ↩︎
Sorrells et al. Human hippocampal neurogenesis in aging and Alzheimer's disease (2018). 2018. ↩︎